Biodel Inc. (NASDAQ:ALBO) has received an average broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.

Zacks has also assigned Biodel an industry rank of 68 out of 265 based on the ratings given to related companies.

Shares of Biodel (NASDAQ:ALBO) traded up 1.7775% during midday trading on Friday, reaching $19.4395. 8,034 shares of the company were exchanged. The firm has a 50-day moving average of $23.42 and a 200 day moving average of $15.92. The firm’s market capitalization is $122.31 million. Biodel has a 52 week low of $6.66 and a 52 week high of $37.69.

COPYRIGHT VIOLATION NOTICE: “Zacks: Biodel Inc. (ALBO) Receives Consensus Rating of “Hold” from Analysts” was posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international trademark and copyright legislation. The original version of this report can be read at http://www.watchlistnews.com/zacks-biodel-inc-albo-receives-consensus-rating-of-hold-from-analysts/1060098.html.

Biodel Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

5 Day Chart for NASDAQ:ALBO

Get a free copy of the Zacks research report on Biodel (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.